ProNAi Therapeutics inked a deal with Novosom to enable delivery of its DNAi®-based cancer therapeutics. "The successful delivery of nucleic acid-based drugs has been the holy grail of the industry for many years, and we are confident that our combined approach will yield promising outcomes,” remarks Richard D. Gill, Ph.D., president and CEO of ProNAi.
ProNAi will license Novosom's Smarticles® liposome technology for use in all human diseases targeted by ProNAi's PNT100 drug candidate. “With this partnership, we have developed a GMP-enabling oligo delivery method that allows ProNAi to submit an IND, and we expect more significant milestones to be met in the near future," states Dr. Gill.
The agreement includes an upfront payment, milestones, and royalties in the form of cash and equity. ProNAi will also retain an option for four additional DNAi targets.